The Retinal Biologics Market Segment, valued at USD 22.5 billion in 2023, is projected to expand to USD 49.5 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period from 2024 to 2032.
Retinal biologics are innovative therapeutic agents used to treat various retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy, and...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian